Cardiologist receives $75M research award
Calum MacRae, MD, chief of cardiovascular medicine at Brigham and Women’s Hospital, received the One Brave Idea research award from the American Heart Association, Verily Life Sciences and AstraZeneca. The award was given to support MacRae’s visionary approach to CHD understanding and prevention and will total $75 million over 5 years, according to a press release.
“I’m grateful to the AHA, Verily and AstraZeneca for believing in my research vision and showing their support by selecting our remarkable team as the recipients of the One Brave Idea award,” MacRae said. “The earliest indicators of CHD remain unknown, both on a genetic and molecular level. If we unearth and characterize novel markers in people genetically prone to heart disease or with early stages of the disease, we can potentially screen the broader population at a younger age to identify those same markers and discover preventive or pre-disease interventions that can break the cascade toward the disease.”
The One Brave Idea award was launched in January as the largest one-time award to find a cure for CHD, according to the release. Besides funding, MacRae will have access to the three sponsors’ resources.
“AstraZeneca, AHA and Verily share a common purpose and passion for patients and science,” Greg Keenan, MD, vice president and head of U.S. medical affairs of AstraZeneca, said in the release. “We believe that this collaboration will ignite and inspires ideas, opening the door to find a big brave solution. Dr. MacRae’s research not only has the potential to advance our understanding of CHD and its underlying consequences but also allows us to combine resources to take a truly innovative and multidisciplinary approach in addressing [CVD].”